TY - JOUR
T1 - Gut Hormones in Heart Failure
AU - Deis, Tania
AU - Goetze, Jens P
AU - Kistorp, Caroline
AU - Gustafsson, Finn
PY - 2024/11
Y1 - 2024/11
N2 - Heart failure (HF) is a syndrome affecting all organ systems. While some organ interactions have been studied intensively in HF (such as the cardiorenal interaction), the endocrine gut has to some degree been overlooked. However, there is growing evidence of direct cardiac effects of several hormones secreted from the gastrointestinal tract. For instance, GLP-1 (glucagon-like peptide-1), an incretin hormone secreted from the distal intestine following food intake, has notable effects on the heart, impacting heart rate and contractility. GLP-1 may even possess cardioprotective abilities, such as inhibition of myocardial ischemia and cardiac remodeling. While other gut hormones have been less studied, there is evidence suggesting cardiostimulatory properties of several hormones. Moreover, it has been reported that patients with HF have altered bioavailability of numerous gastrointestinal hormones, which may have prognostic implications. This might indicate an important role of gut hormones in cardiac physiology and pathology, which may be of particular importance in the failing heart. We present an overview of the current knowledge on gut hormones in HF, focusing on HF with reduced ejection fraction, and discuss how these hormones may be regulators of cardiac function and central hemodynamics. Potential therapeutic perspectives are discussed, and knowledge gaps are highlighted herein.
AB - Heart failure (HF) is a syndrome affecting all organ systems. While some organ interactions have been studied intensively in HF (such as the cardiorenal interaction), the endocrine gut has to some degree been overlooked. However, there is growing evidence of direct cardiac effects of several hormones secreted from the gastrointestinal tract. For instance, GLP-1 (glucagon-like peptide-1), an incretin hormone secreted from the distal intestine following food intake, has notable effects on the heart, impacting heart rate and contractility. GLP-1 may even possess cardioprotective abilities, such as inhibition of myocardial ischemia and cardiac remodeling. While other gut hormones have been less studied, there is evidence suggesting cardiostimulatory properties of several hormones. Moreover, it has been reported that patients with HF have altered bioavailability of numerous gastrointestinal hormones, which may have prognostic implications. This might indicate an important role of gut hormones in cardiac physiology and pathology, which may be of particular importance in the failing heart. We present an overview of the current knowledge on gut hormones in HF, focusing on HF with reduced ejection fraction, and discuss how these hormones may be regulators of cardiac function and central hemodynamics. Potential therapeutic perspectives are discussed, and knowledge gaps are highlighted herein.
KW - Animals
KW - Gastrointestinal Hormones/metabolism
KW - Glucagon-Like Peptide 1/metabolism
KW - Heart Failure/physiopathology
KW - Hemodynamics/physiology
KW - Humans
KW - Stroke Volume/physiology
KW - heart failure
KW - gastrointestinal hormones
KW - myocardium
KW - heart
KW - hemodynamics
UR - http://www.scopus.com/inward/record.url?scp=85209186493&partnerID=8YFLogxK
U2 - 10.1161/CIRCHEARTFAILURE.124.011813
DO - 10.1161/CIRCHEARTFAILURE.124.011813
M3 - Review
C2 - 39498569
SN - 1941-3289
VL - 17
JO - Circulation. Heart failure
JF - Circulation. Heart failure
IS - 11
M1 - e011813
ER -